Work

Donanemab therapy in Alzheimer’s disease with mild cognitive impairment: Convergent amyloid, tau, and plasma biomarker normalization with cognitive improvement

Year: 2026

Type: article

Abstract: Donanemab therapy in Alzheimer's disease with mild cognitive impairment: Convergent amyloid, tau, and plasma biomarker normalization with cognitive improvementRecently, I read with

Source: The Journal of Prevention of Alzheimer s Disease

DOI: 10.1016/j.tjpad.2026.100533

Authors: Limoran Tang, Yun Xu, Hui Zhao

Institutions: Nanjing Drum Tower Hospital, Nanjing University, State Key Laboratory of Pharmaceutical Biotechnology

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,060

Funders: National Natural Science Foundation of China, Government of Jiangsu Province, Key Project of Science and Technology Development of Nanjing Medicine

Awards: G1249271618, G1833764936, G2487689736, G3852078645, G6651265786, G6987625105, G7915384717

OpenAlex ID: W7135240674

FWCI:

Cites: 4

Cited by:

Related to: